ATE151292T1 - Förderung des hepatozytwachstums mit hepatozytwachstumsfaktor und gamma-interferon - Google Patents

Förderung des hepatozytwachstums mit hepatozytwachstumsfaktor und gamma-interferon

Info

Publication number
ATE151292T1
ATE151292T1 AT92912541T AT92912541T ATE151292T1 AT E151292 T1 ATE151292 T1 AT E151292T1 AT 92912541 T AT92912541 T AT 92912541T AT 92912541 T AT92912541 T AT 92912541T AT E151292 T1 ATE151292 T1 AT E151292T1
Authority
AT
Austria
Prior art keywords
hepatocyt
growth
promoting
growth factor
gamma
Prior art date
Application number
AT92912541T
Other languages
English (en)
Inventor
Paula M Jardieu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE151292T1 publication Critical patent/ATE151292T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92912541T 1991-06-10 1992-05-19 Förderung des hepatozytwachstums mit hepatozytwachstumsfaktor und gamma-interferon ATE151292T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/712,284 US5227158A (en) 1991-06-10 1991-06-10 Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon

Publications (1)

Publication Number Publication Date
ATE151292T1 true ATE151292T1 (de) 1997-04-15

Family

ID=24861484

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92912541T ATE151292T1 (de) 1991-06-10 1992-05-19 Förderung des hepatozytwachstums mit hepatozytwachstumsfaktor und gamma-interferon

Country Status (12)

Country Link
US (1) US5227158A (de)
EP (1) EP0606210B1 (de)
JP (1) JPH06508148A (de)
AT (1) ATE151292T1 (de)
AU (1) AU655653B2 (de)
CA (1) CA2109434A1 (de)
DE (1) DE69218956T2 (de)
DK (1) DK0606210T3 (de)
ES (1) ES2101849T3 (de)
GR (1) GR3023613T3 (de)
WO (1) WO1992022321A1 (de)
ZA (1) ZA923980B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
WO1993023550A2 (en) * 1992-05-18 1993-11-25 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
US5763584A (en) * 1992-05-18 1998-06-09 Genentech, Inc. Receptor activation with hepatocyte growth factor agonists
CA2144081C (en) * 1992-09-16 2004-11-30 Filip Roos Protection against liver damage by hgf
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
JP3680114B2 (ja) * 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5696086A (en) * 1994-11-03 1997-12-09 Genentech, Inc. Methods and kits using macrophage stimulating protein
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5855918A (en) * 1995-09-12 1999-01-05 Genentech, Inc. Cystic fibrosis therapy
WO1997012629A1 (en) * 1995-10-05 1997-04-10 Genentech, Inc. Improved angiogenesis using hepatocyte growth factor
AU7389496A (en) * 1995-10-05 1997-04-28 Genentech Inc. Methods and compositions for treating vascular stenosis
CN1055517C (zh) * 1996-03-29 2000-08-16 唐禾天 叶片转子式发动机
US6280739B1 (en) 1996-04-18 2001-08-28 Genetics Institute, Inc. Method of inhibiting angiogenesis using secreted proteins
JP2000515735A (ja) * 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
EP1351707B9 (de) * 2001-01-09 2012-01-25 Baylor Research Institute Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
IL165392A0 (en) * 2002-06-05 2006-01-15 Genentech Inc Compositions and methods for liver growth and liver protection
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
PT1718677E (pt) * 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
US20050244959A1 (en) * 2004-03-30 2005-11-03 Anne Corlu Methods for inducing active hepatocytes proliferation, kits using such methods and uses of said kits
LT1781698T (lt) * 2004-07-20 2016-09-26 Genentech, Inc. Į angiopoetiną panašaus baltymo 4 kompozicijos ir panaudojimo būdai
CA2575402A1 (en) * 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
EP1838736B1 (de) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto-bindende moleküle
CN101193910A (zh) 2005-04-15 2008-06-04 健泰科生物技术公司 HGFβ链变体
WO2008005531A2 (en) * 2006-07-07 2008-01-10 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands
US8236761B2 (en) * 2006-07-07 2012-08-07 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
CA2716670A1 (en) * 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and her antagonists
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US9676849B2 (en) 2012-01-10 2017-06-13 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
US11077132B2 (en) 2015-02-04 2021-08-03 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
CN115181778A (zh) 2015-02-04 2022-10-14 百时美施贵宝公司 选择治疗性分子的方法
RU2720451C1 (ru) * 2019-05-06 2020-04-29 Анастасия Юрьевна Лаптиёва Способ стимуляции пострезекционной пролиферации гепатоцитов путем внутрипеченочного введения цианокобаламина

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
EP0294160A1 (de) * 1987-06-02 1988-12-07 Schering Corporation Behandlung von chronischer Hepatitis B mit einer Mischung menschlicher rekombinanter Alpha- und Gamma-Interferone
US4973478A (en) * 1987-07-20 1990-11-27 Allelix Biopharmaceuticals, Inc. Treating inflammation with hepatocyte stimulating factor interferon β2
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders

Also Published As

Publication number Publication date
DK0606210T3 (da) 1997-05-05
ZA923980B (en) 1993-12-01
CA2109434A1 (en) 1992-12-11
EP0606210B1 (de) 1997-04-09
JPH06508148A (ja) 1994-09-14
EP0606210A1 (de) 1994-07-20
ES2101849T3 (es) 1997-07-16
US5227158A (en) 1993-07-13
AU2144192A (en) 1993-01-12
GR3023613T3 (en) 1997-08-29
DE69218956D1 (de) 1997-05-15
AU655653B2 (en) 1995-01-05
WO1992022321A1 (en) 1992-12-23
DE69218956T2 (de) 1997-07-31

Similar Documents

Publication Publication Date Title
DE69218956D1 (de) Förderung des hepatozytwachstums mit hepatozytwachstumsfaktor und gamma-interferon
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
ATE270111T1 (de) Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
DE3583849D1 (de) Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
ATE219674T1 (de) Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
DK1316308T3 (da) Transdermalt terapeutisk plaster med capsaicin og capsaicin-analoger
MX9203294A (es) Factor de estimulacion de aniquilador natural.
ATE104854T1 (de) Pharmazeutische zusammensetzung zur behandlung von osteoporose.
BR8603315A (pt) Processo para produzir um implante de liberacao controlada;implante usado no processo;processo para purificar e concentrar hormonio de crescimento biologicamente ativo em uma forma adequada para incorporacao em um implante para administracao subcutanea
DE68905438D1 (de) Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose.
DE60237721D1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
DE68909267D1 (de) Medikament zur Behandlung von fibrotischer Störung und antifibrotische Verbindung.
DK155491D0 (da) Behandling af patienter med kronisk leversygdom
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
ATE111357T1 (de) Synergetische immunostimulierende zusammensetzung und ihre verwendung.
ATE229981T1 (de) Glykolisierte cytokine
PT1016414E (pt) Hormona de crescimento humano para estimular a hematopoiese e a reconstituicao imnologica apos transplante de celulas estaminais hematopoieticas em humanos
Raptopoulou et al. Interferon treatment of chronic active hepatitis B: Effect of a 6 month therapeutic regimen
DK222988D0 (da) Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer
Rguez-Moreno et al. A randomized trial of somatostatin (S) versus vasopresin plus nitroglycerin (V/N) in the treatment of acute variceal bleeding (AVB)
DK0427633T3 (da) Anvendelse af et polypeptid med gammainterferonaktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af primitiv pleuracancer
ATE99954T1 (de) Verwendung bestimmter gamma-interferone zur behandlung von krebs des ovars.
TW217382B (de)
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon